Skip to Content

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Fluidigm Announces Conference Call and Webcast of Third Quarter 2021 Financial Results
SOUTH SAN FRANCISCO, Calif. , Oct. 20, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will report third quarter 2021 financial results on Monday,
View HTML
Toggle Summary Fluidigm 2021 IMC Summit Focuses on ‘Uncovering Spatial Biology’
Latest Imaging Mass Cytometry Discoveries in Infectious Disease, Immuno-Oncology and the Tumor Microenvironment from Expert Users of the Technology SOUTH SAN FRANCISCO, Calif. , Oct. 18, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a
View HTML
Toggle Summary Fluidigm Announces New Co-Marketing Program under Collaboration Agreement with Visiopharm, Offering AI-Based Image Analysis Software
Native Reading of Hyperion Imaging System Data Files on the Visiopharm Platform to Streamline Data Analysis for Researchers SOUTH SAN FRANCISCO, Calif. , Oct. 12, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life
View HTML
Toggle Summary Fluidigm Announces Collaboration Agreement with Karolinska Institutet to Accelerate Customer Adoption of New CyTOF XT
Department of Women’s and Children’s Health to Work with Fluidigm on CyTOF Research Applications, Product Development SOUTH SAN FRANCISCO, Calif. , Sept. 28, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through
View HTML
Toggle Summary Fluidigm to Participate in the Cantor Virtual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , Sept. 02, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that Chris Linthwaite , President and CEO, and Vikram Jog, Chief
View HTML
Toggle Summary CyTOF and Maxpar Direct Technologies Utilized in Study Characterizing Immune and Inflammatory Responses in Pregnant Women Infected with SARS-CoV-2
Findings in Nature Communications Provide Insights That May Help Guide Patient Care Research Study Conducted in Collaboration with Fluidigm’s Therapeutic Insights Services SOUTH SAN FRANCISCO, Calif. , Aug. 31, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology
View HTML
Toggle Summary Fluidigm to Participate in UBS Genomics 2.0 and MedTech Innovations Summit
SOUTH SAN FRANCISCO, Calif. , Aug. 09, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that company management will participate in the following investor
View HTML
Toggle Summary Fluidigm Announces Second Quarter 2021 Financial Results with Total Revenue of $31.0 Million
Base business rebounds. Promising early reception to 4th generation mass cytometry instrument. Services business achieves quarterly revenue record of $6.6 million . SOUTH SAN FRANCISCO, Calif. , Aug. 05, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools
View HTML
Toggle Summary Fluidigm Announces Collaboration Agreement with Imaging CRO ImaBiotech to Increase Biopharma Access to Imaging Mass Cytometry
Collaboration Focusing on Advancing CRO Capabilities in Drug Development Utilizing the Hyperion Imaging System SOUTH SAN FRANCISCO, Calif. , Aug. 05, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through
View HTML
Toggle Summary Fluidigm Announces Co-Marketing Agreement with Ultivue for Biomarker Imaging Solutions for Precision Medicine
Objective of Agreement is Comprehensive Portfolio for Biomarker Discovery and Drug Development SOUTH SAN FRANCISCO, Calif. , Aug. 05, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health
View HTML